ASTRAZENECA PLC

AZN

Explore Our Financial Data > Companies > ASTRAZENECA PLC

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AZN
CIK	0000901832
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, United Kingdom, CB2 0AA
Website	astrazeneca.com
Phone	011 44 20 7304 5000
CEO	Pascal Soriot
Employees	83,500

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$77.01 billion
Pre-Tax Income	$30.88 billion
Net Income	$30.88 billion
Net Income to Common	$30.90 billion
EPS	$6.54

View All

Balance Sheet

Cash	$5.71 billion
Assets	$114.07 billion
Liabilities	$65.36 billion
Common Equity	$11.96 billion
Liabilities & Equity	$112.63 billion

View All

Cash Flow Statement

Net Income	$30.88 billion
Cash From Operating Activities	$14.58 billion
Cash From Investing Activities	$-6.81 billion
Cash From Financing Activities	$-7.54 billion
Change in Cash	$223.00 million

View All

Calculations

NOPAT	$32.56 billion
EBITDA	$36.61 billion
Price to Earnings	$0.41
Price to Book	$1.06
ROE	71.20%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Syneron Bio Announces Completion of $150 Million Series B Financing

Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Decheng Capital, and CDH VGC. Additional investors included a wholly owned subsidiary of the Abu Dhabi Investment Authority ("ADIA"), True Light Capital, — an independent, wholly-owned subsidiary of Temasek, Qiming Venture Partners, BioTrack Capita

Article Link

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Astrazeneca (AZN) concluded the recent trading session at $203.49, signifying a +1.37% move from its prior day's close.

Article Link

Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp

AstraZeneca PLC (NYSE:AZN) is one of the best pharma stocks to invest in now. AstraZeneca PLC (NYSE:AZN) received a rating update from Guggenheim on March 30. The firm lifted the price target on the stock to 16,500 GBp from 16,000 GBp, reiterating a Buy rating on the shares. The rating update came as the firm […]

Article Link

Here Are Thursday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Astra-Zeneca, Brinker, e.l.f. Beauty, Freeport-McMoran, Vale, Wingstop, Wix.com, and More

Pre-Market Stock Futures: Risk-on appeared back, at least for the last two days, as the stock market put together another rally on Wednesday, with hopes for an end to the war in Iran and some solid economic data teaming up to push stocks higher, though not at the frenetic level of Tuesday’s rally. However, the ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Astra-Zeneca, Brinker, e.l.f. Beauty, Freeport-McMoran, Vale, Wingstop, Wix.com, and More

Article Link

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

WILMINGTON, Del., April 02, 2026--Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

Article Link